Cargando…

Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis

Introduction Invasive breast cancer with neuroendocrine differentiation is a rare subtype of breast malignancy. Due to frequent changes in the definition of these lesions, the correct diagnosis, estimation of exact prevalence, and clinical behaviour of this entity may be challenging. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Krawczyk, Natalia, Röwer, Rowena, Anlauf, Martin, Muntanjohl, Caja, Baldus, Stephan Ernst, Neumann, Monika, Banys-Paluchowski, Maggie, Otten, Sabine, Luczak, Katharina, Ruckhäberle, Eugen, Mohrmann, Svjetlana, Hoffmann, Jürgen, Kaleta, Thomas, Jaeger, Bernadette, Esposito, Irene, Fehm, Tanja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747900/
https://www.ncbi.nlm.nih.gov/pubmed/35027862
http://dx.doi.org/10.1055/a-1557-1280
_version_ 1784630940584116224
author Krawczyk, Natalia
Röwer, Rowena
Anlauf, Martin
Muntanjohl, Caja
Baldus, Stephan Ernst
Neumann, Monika
Banys-Paluchowski, Maggie
Otten, Sabine
Luczak, Katharina
Ruckhäberle, Eugen
Mohrmann, Svjetlana
Hoffmann, Jürgen
Kaleta, Thomas
Jaeger, Bernadette
Esposito, Irene
Fehm, Tanja
author_facet Krawczyk, Natalia
Röwer, Rowena
Anlauf, Martin
Muntanjohl, Caja
Baldus, Stephan Ernst
Neumann, Monika
Banys-Paluchowski, Maggie
Otten, Sabine
Luczak, Katharina
Ruckhäberle, Eugen
Mohrmann, Svjetlana
Hoffmann, Jürgen
Kaleta, Thomas
Jaeger, Bernadette
Esposito, Irene
Fehm, Tanja
author_sort Krawczyk, Natalia
collection PubMed
description Introduction Invasive breast cancer with neuroendocrine differentiation is a rare subtype of breast malignancy. Due to frequent changes in the definition of these lesions, the correct diagnosis, estimation of exact prevalence, and clinical behaviour of this entity may be challenging. The aim of this study was to evaluate the prevalence, clinical features, and outcomes in a large cohort of patients with breast cancer with neuroendocrine differentiation. Patients Twenty-seven cases of breast cancer with neuroendocrine differentiation have been included in this analysis. Twenty-one cases were identified by systematic immunohistochemical re-evaluation of 465 breast cancer specimens using the neuroendocrine markers chromogranin A and synaptophysin, resulting in a prevalence of 4.5%. A further six cases were identified by a review of clinical records. Results Median age at the time of diagnosis was 61 years. 70% of patients had T2 – 4 tumors and 37% were node-positive. The most common immunohistochemical subtype was HR-positive/HER2-negative (85%). 93% were positive for synaptophysin and 48% for chromogranin A. Somatostatin receptor type 2A status was positive in 12 of 24 analyzed tumors (50%). Neuroendocrine-specific treatment with somatostatin analogues was administered in two patients. The 5-year survival rate was 70%. Conclusions Breast cancer with neuroendocrine differentiation is mostly HR-positive/HER2-negative and the diagnosis is made at a higher TNM stage than in patients with conventional invasive breast carcinoma. Moreover, breast cancer with neuroendocrine differentiation was found to be associated with impaired prognosis in several retrospective trials. Due to somatostatin receptor 2A expression, somatostatin receptor-based imaging can be used and somatostatin receptor-targeted therapy can be offered in selected cases.
format Online
Article
Text
id pubmed-8747900
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-87479002022-01-12 Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis Krawczyk, Natalia Röwer, Rowena Anlauf, Martin Muntanjohl, Caja Baldus, Stephan Ernst Neumann, Monika Banys-Paluchowski, Maggie Otten, Sabine Luczak, Katharina Ruckhäberle, Eugen Mohrmann, Svjetlana Hoffmann, Jürgen Kaleta, Thomas Jaeger, Bernadette Esposito, Irene Fehm, Tanja Geburtshilfe Frauenheilkd Introduction Invasive breast cancer with neuroendocrine differentiation is a rare subtype of breast malignancy. Due to frequent changes in the definition of these lesions, the correct diagnosis, estimation of exact prevalence, and clinical behaviour of this entity may be challenging. The aim of this study was to evaluate the prevalence, clinical features, and outcomes in a large cohort of patients with breast cancer with neuroendocrine differentiation. Patients Twenty-seven cases of breast cancer with neuroendocrine differentiation have been included in this analysis. Twenty-one cases were identified by systematic immunohistochemical re-evaluation of 465 breast cancer specimens using the neuroendocrine markers chromogranin A and synaptophysin, resulting in a prevalence of 4.5%. A further six cases were identified by a review of clinical records. Results Median age at the time of diagnosis was 61 years. 70% of patients had T2 – 4 tumors and 37% were node-positive. The most common immunohistochemical subtype was HR-positive/HER2-negative (85%). 93% were positive for synaptophysin and 48% for chromogranin A. Somatostatin receptor type 2A status was positive in 12 of 24 analyzed tumors (50%). Neuroendocrine-specific treatment with somatostatin analogues was administered in two patients. The 5-year survival rate was 70%. Conclusions Breast cancer with neuroendocrine differentiation is mostly HR-positive/HER2-negative and the diagnosis is made at a higher TNM stage than in patients with conventional invasive breast carcinoma. Moreover, breast cancer with neuroendocrine differentiation was found to be associated with impaired prognosis in several retrospective trials. Due to somatostatin receptor 2A expression, somatostatin receptor-based imaging can be used and somatostatin receptor-targeted therapy can be offered in selected cases. Georg Thieme Verlag KG 2021-11-18 /pmc/articles/PMC8747900/ /pubmed/35027862 http://dx.doi.org/10.1055/a-1557-1280 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Krawczyk, Natalia
Röwer, Rowena
Anlauf, Martin
Muntanjohl, Caja
Baldus, Stephan Ernst
Neumann, Monika
Banys-Paluchowski, Maggie
Otten, Sabine
Luczak, Katharina
Ruckhäberle, Eugen
Mohrmann, Svjetlana
Hoffmann, Jürgen
Kaleta, Thomas
Jaeger, Bernadette
Esposito, Irene
Fehm, Tanja
Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis
title Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis
title_full Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis
title_fullStr Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis
title_full_unstemmed Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis
title_short Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis
title_sort invasive breast carcinoma with neuroendocrine differentiation: a single-center analysis of clinical features and prognosis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747900/
https://www.ncbi.nlm.nih.gov/pubmed/35027862
http://dx.doi.org/10.1055/a-1557-1280
work_keys_str_mv AT krawczyknatalia invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis
AT rowerrowena invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis
AT anlaufmartin invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis
AT muntanjohlcaja invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis
AT baldusstephanernst invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis
AT neumannmonika invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis
AT banyspaluchowskimaggie invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis
AT ottensabine invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis
AT luczakkatharina invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis
AT ruckhaberleeugen invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis
AT mohrmannsvjetlana invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis
AT hoffmannjurgen invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis
AT kaletathomas invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis
AT jaegerbernadette invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis
AT espositoirene invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis
AT fehmtanja invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis